Ser422
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser422  -  SMAD3 (human)

Site Information
GsPsIRCssVs____   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449603

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 ) , phosphopeptide mapping ( 2 ) , western blotting ( 1 )
Disease tissue studied:
testicular cancer ( 1 )
Relevant cell line - cell type - tissue:
Leydig ( 1 ) , MA-10 (testicular) ( 1 ) , Mv1Lu (pulmonary) ( 2 )

Upstream Regulation
Treatments:
cAMP_analog ( 1 ) , TGF-beta ( 1 , 2 )

Downstream Regulation
Effects of modification on biological processes:
transcription, altered ( 2 ) , transcription, induced ( 1 )

References 

1

Park E, et al. (2014) Transforming Growth Factor-β1 Signaling Represses Testicular Steroidogenesis through Cross-Talk with Orphan Nuclear Receptor Nur77. PLoS One 9, e104812
25140527   Curated Info

2

Liu X, et al. (1997) Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A 94, 10669-74
9380693   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.